Summary: 

Differences between eGFRcys and eGFRcr are common among patients with CKD. These differences can provide information about ESKD and mortality risks, and so eGFRcys and eGFRcr should be monitored among high risk patients with CKD.

Objectives:

At the conclusion of this activity, the learner should be able to:

• Describe the utility of cystatin eGFRcys
• Interpret the differences between eGFRcys and eGFRcr
• Identify the association of eGFRdiffcys-cr with end-stage kidney disease (ESKD) and mortality

Bio: Muskan Agarwal

I am an internal medicine PGY-2, born and raised in Texas. Hobbies include hiking, reading, traveling.

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.